Skip to content

Early POstoperative BIomarkers in PancreatoDuodenectomy: a Spanish Nationwide Study

Early POstoperative BIomarkers in PancreatoDuodenectomy as Predictors of Complications: a Spanish Nationwide Multicentric Validation Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04342923
Acronym
EPOBIPD
Enrollment
525
Registered
2020-04-13
Start date
2021-03-01
Completion date
2022-05-31
Last updated
2021-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreaticoduodenectomy

Keywords

PANCREATICODUODENECTOMY, COMPLICATIONS, PANCREATIC FISTULA, SCORE, BIOMARKERS

Brief summary

AIMS: To recruit a large nationwide Spanish series in order to register PF rate and other common morbidity after PD, and to perform external validation of the aforementioned score, as well as to analyze other postoperative blood parameters and biomarkers associated with complications. METHODS: Observational prospective and multicentric cohort study to perform external validation of the above-mentioned score. All Spanish centers/units performing PD are invited to include participants. Patients will be consecutively recruited during an 8-10 months period, regardless of their annual volume of pancreatic surgery. Study variables will be hemogram parameters on POD1 and POD2 (specifically lymphocytes), other parameters and biomarkers (RCP, lactate, procalcitonin, amylase, lipase, albumin) and the common variables concerning PD studies. LIMITATIONS: Heterogeneity in perioperative management and in blood analysis measuring since this is a multicenter study. Possibility of underestimating the PF rate in patients without surgical drainage. Finally, the cases of mini-invasive approach or pancreatogastrostomy will receive a specific subgroup analysis since the score was designed on a series of open PD and pancreatojejunostomy.

Detailed description

BACKGROUND: Complications after pancreatoduodenectomy (PD) are common and pancreatic fistula (PF) is among the most relevant ones. There are few studies analyzing blood parameters determined in the early postoperative period which behave as morbidity predictors. One of them defined a new and simple prognostic score based on lymphocytes count on the first postoperative day (POD1) and reactive C protein (RCP) on POD2. The internal validation statistics of the score designed in the mentioned work were satisfactory. However, that score was described in a short unicentric series EXPECTED SAMPLE SIZE: Expected sample size is approximately 500 patients, which will show error \<7.2% (with 95% confidence) for estimation score´s sensitivity and specificity. We have assumed that the PF rate is around 30%. QUALITY CONTROL: The STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidelines for the correct communication and publication of observational studies will be followed. Likewise, in order to validate the aforementioned score, Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) will be added. The only expected failure of the 20 items that compose the TRIPOD is 6b (notify the actions for masking the analysis), since it is not applicable in our case. The inclusion of patients operated on with a mini-invasive approach (laparoscopic or robotic) or the use of other anastomoses (pancreatogastrostomy) or reconstruction (Roux-en-Y) differs from the technique used in the series with which the score was originally defined (allof them, open PD with pancreato-jejunostomy and, mostly part, tutored ducto-mucosal suture and Child's single loop reconstruction). If discrepancies are detected, the corresponding subgroup analysis will be performed. Cases of conversion from a mini-invasive to open approach will be counted as such (intention-to-treat analysis).

Interventions

OTHERNo intervention

Blood analysis

Sponsors

Hospital Clínico Universitario de Valladolid
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* benign or malignant condition requiring surgical treatment by PD. * Signing the informed consent form

Exclusion criteria

* Intra-operative findings of unresectability (pancreatic resection not be completed or palliative procedure performed) * Other types of pancreatic resection (enucleations, distal and total pancreatectomies), as well as multivisceral resective procedures. * Intraoperative radiotherapy * ASA IV patients

Design outcomes

Primary

MeasureTime frameDescription
Pancreatic fistula rate90 days since PDPancreatic fistula including biochemical, grade B and grade C according to ISGPS updated criteria 2016

Secondary

MeasureTime frameDescription
Clinically relevant pancreatic fistula90 days since PDPancreatic fistula including grade B and grade C according to ISGPS updated criteria 2016
Overall complications90 days since PDPresence of any kind of complications including grades I to V according to Dindo-Clavien Classification
Severe morbidity90 days since PDPresence of any kind of complications including grades IIIa to V according to Dindo-Clavien Classification
Mortality90 days since PDPatient´s death
Comprehensive Complication Index90 days since PDPostoperative morbidity index (0-100 points) obteined by using formula described by Slankamenac et al Ann Surg 2013

Countries

Spain

Contacts

Primary ContactMario Rodriguez-Lopez, MD, PhD
mariorodriguezlopez@gmail.com983420000
Backup ContactCarlos A Jezieniecki-Fernandez, MD
carlos.jezieniecki@gmail.com983420000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026